These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 19109322)
1. Commentary: The balance between marketing and safety. Beard K BMJ; 2008 Dec; 337():a2996. PubMed ID: 19109322 [No Abstract] [Full Text] [Related]
2. The marketplace can't give us the drug safety data we need. Avorn J MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636 [No Abstract] [Full Text] [Related]
3. Evidence of comparative efficacy should have a formal role in European drug approvals. Sorenson C; Naci H; Cylus J; Mossialos E BMJ; 2011 Sep; 343():d4849. PubMed ID: 21896610 [No Abstract] [Full Text] [Related]
4. Tysabri back on market. Sheridan C Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111 [No Abstract] [Full Text] [Related]
5. Pros and cons of off-label promotion investigations and prosecutions. Loucks MK Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041 [No Abstract] [Full Text] [Related]
8. The influence of the pharmaceutical industry in medicine. Jelinek GA; Neate SL J Law Med; 2009 Oct; 17(2):216-23. PubMed ID: 19998591 [TBL] [Abstract][Full Text] [Related]
11. Overview of the animal health drug development and registration process: an industry perspective. Hunter RP; Shryock TR; Cox BR; Butler RM; Hammelman JE Future Med Chem; 2011 May; 3(7):881-6. PubMed ID: 21644833 [TBL] [Abstract][Full Text] [Related]
12. [From the chemical product to the authorization of drug marketing]. Caulin C Rev Prat; 2002 Mar; 52(5):486-90. PubMed ID: 11949499 [TBL] [Abstract][Full Text] [Related]
13. Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting. Lilienfeld DE Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):381-5. PubMed ID: 15170767 [TBL] [Abstract][Full Text] [Related]
14. Genomics and drug toxicity. Lord PG; Papoian T Science; 2004 Oct; 306(5696):575. PubMed ID: 15498974 [No Abstract] [Full Text] [Related]
15. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here? Stevens JL Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225 [TBL] [Abstract][Full Text] [Related]
17. Companies line up for hereditary angioedema market. Huggett B Nat Biotechnol; 2008 Apr; 26(4):364-5. PubMed ID: 18392002 [No Abstract] [Full Text] [Related]
18. A new approach to drug development. Mayer D N Engl J Med; 2006 Nov; 355(19):2045; author reply 2046. PubMed ID: 17099949 [No Abstract] [Full Text] [Related]
19. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. Reed SD; Anstrom KJ; Seils DM; Califf RM; Schulman KA Health Aff (Millwood); 2008; 27(5):w360-70. PubMed ID: 18682441 [TBL] [Abstract][Full Text] [Related]
20. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk. Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527 [No Abstract] [Full Text] [Related] [Next] [New Search]